# Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

> **NCT01660633** · PHASE2 · COMPLETED · sponsor: **Acrotech Biopharma Inc.** · enrollment: 61 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
- **OTHER:** Autologous Transplantation

## Key facts

- **NCT ID:** NCT01660633
- **Lead sponsor:** Acrotech Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2014-02
- **Final completion:** 2014-08
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-04-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01660633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01660633, "Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01660633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*